




## The PIPC Blog

# Chairman's Corner: Will ICER's Response to Attacks on the QALY Quiet the Critics?: A Reply from the Partnership to Improve Patient Care

2/8/2019



In response to a recent blog post entitled [“Will ICER's Response to Attacks on the QALY Quiet the Critics?”](#) (December 18, 2018) we must unfortunately reply: Absolutely not. Regrettably, ICER's response suggests that for patients, the only options are a) a metric that is widely acknowledged to discriminate against the elderly and people with disabilities, or b) a metric that ignores elements of value that are critically important to patients. Patients need another option, and PIPC is committed to supporting it.

We appreciate the opportunity to respond to comments made by the researchers at Tufts on our concerns around the QALY. We respect researchers who have invested long years and considerable expertise in QALY-based value assessment. But we also respectfully suggest that it's time to acknowledge that these assessment tools are dangerous and will never be appropriate for decision-making.

We invite all researchers in the field of value assessment to engage directly with patients and foster an open dialogue, so that we can collectively advance the metrics and utility of value assessment.

### How the QALY discriminates

Because people with disabilities, seniors, and patients with chronic conditions may experience a potential for health that is less than their “healthier” counterparts, treatment that extends or improves their life may result in fewer QALYs than a treatment developed for a non-disabled or younger population where the treatment is able to return the patient to so-called perfect health. As QALYs are



When applied to coverage and reimbursement decisions, the result is discrimination against people with disabilities, a legal violation of the Americans with Disabilities Act when applied by state Medicaid programs and a violation of the statutory ban on use of QALYs when used in Medicare. Both Congress and HHS have recognized this. America's sense of morality and ethic of equality makes it a bridge too far to deny care to those with significant lifetime health needs just because they may never achieve a pre-conceived notion of optimal health.

### **Why must patients forgo incorporating quality of life to avoid discrimination?**

Those who are wed to traditional cost-effectiveness assessments have posited an untenable choice between two flawed metrics: the QALY, which incorporates some measures of value reflecting quantity and quality of life, but discriminates against patients and people with disabilities, or the "equal value of life year gained," the evLYG, which disregards any value of a medicine other than its ability to extend life.

This is a false choice and it further demonstrates that current, conventional cost-effectiveness assessments are not fit for making vital health care decisions.

As the Tufts researchers themselves point out, the "evLYG measure has its own discriminatory implications." Failing to account for symptom and quality of life improvements ignores key aspects of value that are important to patients, and important to different degrees for different patients. However, while the QALY attempts to correct for this, it does not appropriately address this failure because it does not accurately capture quality of life for patients.

Attempts to address the QALY's shortcomings by incorporating more patient-centered measures of value, such as those suggested by the ISPOR Special Task Force, are a valiant effort to seek improvements, but do not address the underlying flaw. We agree that neither the QALY nor the evLYG offers a reliable metric by which to provide a patient-centered measure of a medicine's value to patients, their families, and the health care system.

Rather than resigning to pick between two measures that all agree fall short, and in turn hinder any lasting improvements value assessments can achieve or its utility for patients and our health care system, we must commit to a better path forward.

### **Moving value assessment forward**

We continue to challenge the prevailing notion that patients are unwilling or unable to understand that difficult trade-offs must be made in health care, and therefore incapable of being relied on as partners in the quest for better value in health care. As key stakeholders, we are committed to coming to the table with actionable alternatives and continue to seek out opportunities to collaborate on novel approaches with other experts in the field.

We urge innovative researchers to develop novel ways to measure the value of medicines and other



of health care resources, prioritizing high value care over low value care when that trade off adequately accounts for individual patient value. Unfortunately, today's value assessment tools are incapable of informing these types of decisions.

There are many forward-thinking researchers beginning to take steps to engage with patients to improve value assessment and even move beyond the QALY.

Some researchers are at the cutting edge of value assessment, including those championing multi-decision criteria assessments (MDCA) and open-source models, like the Innovation & Value Initiative (IVI). The National Health Council has [partnered with](#) the University of Maryland to drive the patient voice into value assessment through direct engagement with patients in developing novel methods.

We are devoted to supporting the development of assessment tools and metrics that properly reflect elements of value that matter to patients and people with disabilities without utilizing discriminatory and flawed measures. Through the development of these tools, informed decisions can be made that will truly improve health care.

While the QALY may seem “reasonable” to some, as patients and people with disabilities, we cannot afford to settle for “good enough” when “good enough” discriminates against those who aren't “worth enough.”



[pipc\\_chairmans\\_blog\\_cevr.pdf](#)

**Download File**



[Tweet](#)

Comments are closed.

## Topics

[All](#)

[Alternative Payment Models](#)

[Chairman's Corner](#)

[Patient Centered Research](#)

[PIPC In The News](#)

[PIPC Patient Blog](#)

[PIPC Weekly Update](#)

[Press Releases](#)

[The Data Mine](#)



- 
- [March 2023](#)
  - [February 2023](#)
  - [January 2023](#)
  - [December 2022](#)
  - [November 2022](#)
  - [October 2022](#)
  - [September 2022](#)
  - [August 2022](#)
  - [July 2022](#)
  - [June 2022](#)
  - [May 2022](#)
  - [April 2022](#)
  - [March 2022](#)
  - [February 2022](#)
  - [January 2022](#)
  - [December 2021](#)
  - [November 2021](#)
  - [October 2021](#)
  - [September 2021](#)
  - [August 2021](#)
  - [July 2021](#)
  - [June 2021](#)
  - [May 2021](#)
  - [April 2021](#)
  - [March 2021](#)
  - [February 2021](#)
  - [January 2021](#)
  - [December 2020](#)
  - [November 2020](#)
  - [October 2020](#)
  - [September 2020](#)
  - [August 2020](#)
  - [July 2020](#)
  - [June 2020](#)
  - [May 2020](#)
  - [April 2020](#)
  - [March 2020](#)
  - [February 2020](#)
  - [January 2020](#)
  - [December 2019](#)
  - [November 2019](#)
  - [October 2019](#)



- 
- [June 2019](#)
  - [May 2019](#)
  - [April 2019](#)
  - [March 2019](#)
  - [February 2019](#)
  - [January 2019](#)
  - [December 2018](#)
  - [November 2018](#)
  - [October 2018](#)
  - [September 2018](#)
  - [August 2018](#)
  - [July 2018](#)
  - [June 2018](#)
  - [May 2018](#)
  - [April 2018](#)
  - [March 2018](#)
  - [February 2018](#)
  - [January 2018](#)
  - [December 2017](#)
  - [November 2017](#)
  - [October 2017](#)
  - [September 2017](#)
  - [August 2017](#)
  - [July 2017](#)
  - [June 2017](#)
  - [May 2017](#)
  - [April 2017](#)
  - [March 2017](#)
  - [February 2017](#)
  - [January 2017](#)
  - [December 2016](#)
  - [November 2016](#)
  - [October 2016](#)
  - [September 2016](#)
  - [August 2016](#)
  - [July 2016](#)
  - [June 2016](#)
  - [May 2016](#)
  - [April 2016](#)
  - [March 2016](#)
  - [February 2016](#)
  - [January 2016](#)
  - [December 2015](#)



- 
- [August 2015](#)
  - [July 2015](#)
  - [June 2015](#)
  - [May 2015](#)
  - [April 2015](#)
  - [March 2015](#)
  - [February 2015](#)
  - [January 2015](#)
  - [December 2014](#)
  - [November 2014](#)
  - [October 2014](#)
  - [September 2014](#)
  - [August 2014](#)
  - [July 2014](#)
  - [June 2014](#)
  - [May 2014](#)
  - [April 2014](#)
  - [March 2014](#)
  - [February 2014](#)
  - [January 2014](#)
  - [December 2013](#)
  - [November 2013](#)
  - [October 2013](#)
  - [September 2013](#)
  - [August 2013](#)
  - [July 2013](#)
  - [June 2013](#)
  - [April 2013](#)
  - [March 2013](#)
  - [December 2012](#)
  - [November 2012](#)
  - [February 2012](#)
  - [September 2011](#)
  - [August 2011](#)
  - [July 2011](#)
  - [May 2011](#)
  - [March 2011](#)
  - [November 2010](#)
  - [October 2010](#)
  - [September 2010](#)
  - [August 2010](#)
  - [April 2010](#)
  - [March 2010](#)



---

July 2009

June 2009

May 2009

February 2009

January 2009

December 2008



[The Issues](#)

[Resources](#)

[Blog](#)

[In the News](#)

[Press Releases](#)

[Contact Us](#)

100 M Street, SE – Ste. 750  
Washington, DC 20003



Map data ©2023 Google [Report a map error](#)